Peter Kolchinsky portfolio, Q2 2026
RA Capital Management · 13F for the quarter ending Jun 30, 2026
For Q2 2026, RA Capital Management reported $11.5B across 84 US-listed positions, led by ASND (23.8%), PBLS (6.9%) and RYTM (6.4%). Compared with its filing for Q1 2026, Peter Kolchinsky opened 16 new positions, added to 10, reduced 10 and sold out of 17; 47 positions did not change.
The largest purchase was a new position in PBLS ($791.9M); the largest sale, the sale of the whole position in DNTH ($219.2M).
This is the latest filing on file; the main portfolio page shows the same holdings against today's prices.
Key facts
- 13F portfolio value
- $11.5BQ2 2026
- Positions
- 84
- Largest holding
- ASND 23.8%
- New positions
- 16
- Sold out
- 17
- Filed
- Aug 14, 2026
Holdings as of (Q2 2026), filed with the SEC on . Changes are measured against the filing for Mar 31, 2026. Every tracked investor's Q2 2026 13F.
Bought and sold in Q2 2026
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Parabilis Medicines IncPBLS | ▲ New | +28.93M | $791.9M | 6.88% |
| Hemab Therapeutics HoldingsCOAG | ▲ New | +7.81M | $286.8M | 2.49% |
| Dianthus Therapeutics IncDNTH | ▼ Sold out | −2.61M | $219.2M | 1.90% |
Nuvalent Incno ticker on file | ▼ Reduced 51% | −1.29M | $159M | 1.38% |
| Abivax SAABVX | ▲ New | +1.13M | $150.9M | 1.31% |
| Oruka Therapeutics IncORKA | ▲ New | +1.55M | $148M | 1.29% |
| Praxis Precision MedicinesPRAX | ▼ Sold out | −373.79K | $120.4M | 1.05% |
| Sarepta Therapeutics IncSRPT | ▼ Sold out | −3.9M | $84.9M | 0.74% |
| Edgewise Therapeutics IncEWTX | ▼ Reduced 20% | −2.04M | $82.7M | 0.72% |
| Spyre Therapeutics IncSYRE | ▼ Sold out | −1.62M | $81.8M | 0.71% |
| Artiva Biotherapeutics IncARTV | ▲ Added 82% | +8.1M | $78.6M | 0.68% |
| Intellia Therapeutics IncNTLA | ▲ New | +4.53M | $76.6M | 0.67% |
| Definium Therapeutics IncDFTX | ▲ New | +1.5M | $70.6M | 0.61% |
| Sana Biotechnology IncSANA | ▲ New | +18.75M | $65.4M | 0.57% |
| Vor Biopharma IncVOR | ▼ Reduced 56% | −3M | $55.3M | 0.48% |
| Fulcrum Therapeutics IncFULC | ▼ Sold out | −6.05M | $46.4M | 0.40% |
| Olema Pharmaceuticals IncOLMA | ▼ Sold out | −2.6M | $38.8M | 0.34% |
| Prelude Therapeutics IncPRLD | ▲ New | +6.48M | $34.5M | 0.30% |
| Design Therapeutics IncDSGN | ▼ Sold out | −2.97M | $31.6M | 0.27% |
| Aclaris Therapeutics IncACRS | ▲ Added 87% | +5.92M | $31.3M | 0.27% |
| Q32 Bio IncQTTB | ▲ New | +2.33M | $29.7M | 0.26% |
| Editas Medicine IncEDIT | ▲ New | +8.89M | $28.8M | 0.25% |
| Solid Biosciences IncSLDB | ▲ Added 29% | +2.7M | $26.9M | 0.23% |
| Geron CorpGERN | ▼ Reduced 33% | −20.96M | $26.8M | 0.23% |
| Travere Therapeutics IncTVTX | ▼ Sold out | −746.84K | $22.2M | 0.19% |
| Grail IncGRAL | ▼ Sold out | −428.27K | $22.1M | 0.19% |
| Relmada Therapeutics IncRLMD | ▼ Sold out | −2.95M | $20.5M | 0.18% |
| Altimmune IncALT | ▲ New | +6.5M | $19.8M | 0.17% |
| Faeth Therapeutics IncFTH | ▲ New | +722.02K | $18.1M | 0.16% |
| Sutro Biopharma IncSTRO | ▼ Sold out | −715.31K | $17.8M | 0.15% |
| Aura Biosciences IncAURA | ▲ New | +2.5M | $17.8M | 0.15% |
| Contineum Therapeutics IncCTNM | ▼ Sold out | −1.3M | $16.9M | 0.15% |
| Inspire Med Systems IncINSP | ▼ Sold out | −325.66K | $16.8M | 0.15% |
| Seaport Therapeutics IncSPTX | ▲ New | +700K | $15.2M | 0.13% |
| Hinge Health IncHNGE | ▼ Sold out | −364.61K | $14.1M | 0.12% |
| GeneDx Holdings CorpWGS | ▼ Sold out | −209.89K | $13.5M | 0.12% |
| Atrium Therapeutics IncRNA | ▼ Sold out | −864.1K | $11.6M | 0.10% |
| Acrivon Therapeutics IncACRV | ▲ Added 47% | +3.89M | $6.9M | 0.06% |
| Avalo Therapeutics IncAVTX | ▲ Added 51% | +337.03K | $6.2M | 0.05% |
| Aktis Oncology IncAKTS | ▼ Reduced 13% | −188.68K | $6.1M | 0.05% |
| Xencor IncXNCR | ▲ Added 7.7% | +377.04K | $6.1M | 0.05% |
| Jatt II Acquisition CorpJATT | ▲ New | +500K | $5.7M | 0.05% |
| Maplight Therapeutics IncMPLT | ▼ Sold out | −248.29K | $5M | 0.04% |
| Amanat Acquisition CorpAMAN | ▲ New | +375K | $3.8M | 0.03% |
| Adicet Bio IncACET | ▼ Reduced 21% | −250K | $2.2M | 0.02% |
| Werewolf Therapeutics IncHOWL | ▼ Reduced 64% | −4.29M | $1.5M | 0.01% |
| Rezolute IncRZLT | ▲ Added 2.9% | +265.04K | $1.4M | 0.01% |
| GH Research PLCGHRS | ▼ Reduced 0.5% | −39.88K | $1.1M | 0.01% |
| Zai Lab LtdZLAB | ▲ Added 0.6% | +36.27K | $689.1K | 0.01% |
| Ovid Therapeutics IncOVID | ▼ Reduced 2.0% | −213.03K | $573.1K | 0.00% |
| Bioage Labs IncBIOA | ▲ Added 1.3% | +21K | $514.7K | 0.00% |
| Palatin Technologies IncPTN | ▼ Reduced 11% | −7.88K | $85K | 0.00% |
| Damora Therapeutics IncDMRA | ▲ Added 0.02% | +392 | $10.2K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q1 2026 |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND | Health Care | 23.8% | $2.7B | 10.28M | $266.72 | 9+ qtrs | — |
| 2 | Parabilis Medicines IncPBLS | — | 6.88% | $791.9M | 28.93M | $27.37 | 1 qtr | New |
| 3 | Rhythm Pharmaceuticals IncRYTM | Health Care | 6.43% | $740.2M | 6.67M | $111.03 | 9+ qtrs | No change |
| 4 | Vaxcyte IncPCVX | Health Care | 5.80% | $667M | 11.47M | $58.13 | 9+ qtrs | No change |
| 5 | Sionna Therapeutics IncSION | — | 3.79% | $435.7M | 9.91M | $43.99 | 6 qtrs | No change |
| 6 | Tyra Biosciences IncTYRA | — | 3.39% | $389.6M | 12.2M | $31.94 | 9+ qtrs | No change |
| 7 | Edgewise Therapeutics IncEWTX | Health Care | 2.96% | $341M | 8.39M | $40.63 | 9+ qtrs | ▼ Reduced 20% |
| 8 | Newamsterdam Pharma CompanyNAMS | — | 2.81% | $323.7M | 9.55M | $33.89 | 9+ qtrs | No change |
| 9 | Hemab Therapeutics HoldingsCOAG | — | 2.49% | $286.8M | 7.81M | $36.73 | 1 qtr | New |
| 10 | Septerna IncSEPN | — | 2.04% | $234.3M | 7M | $33.49 | 7 qtrs | No change |
| 11 | Bicara Therapeutics IncBCAX | — | 1.87% | $215.4M | 7.26M | $29.69 | 8 qtrs | No change |
| 12 | Mineralys Therapeutics IncMLYS | — | 1.80% | $207.6M | 7.69M | $26.98 | 9+ qtrs | No change |
| 13 | GH Research PLCGHRS | — | 1.78% | $205.3M | 7.64M | $26.88 | 9+ qtrs | ▼ Reduced 0.5% |
| 14 | Disc Medicine IncIRON | — | 1.56% | $179.2M | 2.45M | $73.14 | 6 qtrs | No change |
| 15 | Spyglass Pharma IncSGP | — | 1.55% | $178.6M | 8.02M | $22.26 | 2 qtrs | No change |
| 16 | Artiva Biotherapeutics IncARTV | — | 1.51% | $174.2M | 17.96M | $9.70 | 8 qtrs | ▲ Added 82% |
| 17 | Janux Therapeutics IncJANX | — | 1.49% | $171.9M | 11.19M | $15.36 | 9+ qtrs | No change |
| 18 | Taysha Gene Therapies IncTSHA | — | 1.39% | $160.4M | 23.56M | $6.81 | 9+ qtrs | No change |
| 19 | BioCryst Pharmaceuticals IncBCRX | — | 1.38% | $158.3M | 15.83M | $10.00 | 3 qtrs | No change |
| 20 | Wave Life Sciences LtdWVE | — | 1.36% | $156.7M | 26.98M | $5.81 | 9+ qtrs | No change |
| 21 | Nuvalent Incno ticker on file | — | 1.34% | $153.9M | 1.25M | $123.50 | 4 qtrs | ▼ Reduced 51% |
| 22 | Abivax SAABVX · ADR | Health Care | 1.31% | $150.9M | 1.13M | $133.26 | 1 qtr | New |
| 23 | Oruka Therapeutics IncORKA | Health Care | 1.29% | $148M | 1.55M | $95.17 | 1 qtr | New |
| 24 | Climb Bio IncCLYM | — | 1.28% | $147.4M | 11.3M | $13.04 | 9+ qtrs | No change |
| 25 | Solid Biosciences IncSLDB | — | 1.05% | $120.2M | 12.04M | $9.99 | 9+ qtrs | ▲ Added 29% |
| 26 | Zai Lab LtdZLAB · ADR | — | 0.95% | $109.1M | 5.74M | $19.00 | 2 qtrs | ▲ Added 0.6% |
| 27 | Ars Pharmaceuticals IncSPRY | — | 0.76% | $87M | 10.86M | $8.01 | 9+ qtrs | No change |
| 28 | Xencor IncXNCR | — | 0.74% | $84.9M | 5.27M | $16.10 | 2 qtrs | ▲ Added 7.7% |
| 29 | Jade Biosciences IncJBIO | — | 0.71% | $81.6M | 3.67M | $22.22 | 5 qtrs | No change |
| 30 | Intellia Therapeutics IncNTLA | — | 0.67% | $76.6M | 4.53M | $16.92 | 1 qtr | New |
| 31 | LB Pharmaceuticals IncLBRX | — | 0.62% | $71.7M | 2.21M | $32.46 | 4 qtrs | No change |
| 32 | Definium Therapeutics IncDFTX | Health Care | 0.61% | $70.6M | 1.5M | $47.04 | 1 qtr | New |
| 33 | Aclaris Therapeutics IncACRS | — | 0.59% | $67.3M | 12.72M | $5.29 | 2 qtrs | ▲ Added 87% |
| 34 | 4D Molecular TherapeuticsFDMT | — | 0.58% | $67.2M | 5.05M | $13.30 | 9+ qtrs | No change |
| 35 | Sana Biotechnology IncSANA | — | 0.57% | $65.4M | 18.75M | $3.49 | 1 qtr | New |
| 36 | Damora Therapeutics IncDMRA | — | 0.54% | $62.4M | 2.4M | $26.01 | 2 qtrs | ▲ Added 0.02% |
| 37 | Monopar Therapeutics IncMNPR | — | 0.54% | $61.8M | 667.21K | $92.59 | 7 qtrs | No change |
| 38 | Acumen Pharmaceuticals IncABOS | — | 0.49% | $56.1M | 20.99M | $2.67 | 9+ qtrs | No change |
| 39 | Geron CorpGERN | — | 0.48% | $54.8M | 42.81M | $1.28 | 9+ qtrs | ▼ Reduced 33% |
| 40 | Rezolute IncRZLT | — | 0.43% | $49.1M | 9.45M | $5.20 | 3 qtrs | ▲ Added 2.9% |
| 41 | Evommune IncEVMN | — | 0.40% | $46.4M | 3.49M | $13.29 | 3 qtrs | No change |
| 42 | Vor Biopharma IncVOR | — | 0.38% | $44.2M | 2.4M | $18.41 | 9+ qtrs | ▼ Reduced 56% |
| 43 | Century Therapeutics IncIPSC | — | 0.38% | $43.5M | 17.75M | $2.45 | 2 qtrs | No change |
| 44 | Aktis Oncology IncAKTS | — | 0.37% | $42.4M | 1.31M | $32.23 | 2 qtrs | ▼ Reduced 13% |
| 45 | Bioage Labs IncBIOA | — | 0.36% | $41M | 1.67M | $24.51 | 2 qtrs | ▲ Added 1.3% |
| 46 | C4 Therapeutics IncCCCC | — | 0.33% | $37.4M | 8M | $4.67 | 3 qtrs | No change |
| 47 | Mirum Pharmaceuticals IncMIRM | Health Care | 0.32% | $37.3M | 318.55K | $117.07 | 2 qtrs | No change |
| 48 | Capricor Therapeutics IncCAPR | — | 0.32% | $36.3M | 1.51M | $24.08 | 3 qtrs | No change |
| 49 | Pepgen IncPEPG | — | 0.31% | $36.1M | 20.06M | $1.80 | 9+ qtrs | No change |
| 50 | Prelude Therapeutics IncPRLD | — | 0.30% | $34.5M | 6.48M | $5.33 | 1 qtr | New |
| 51 | Nkarta IncNKTX | — | 0.27% | $30.6M | 10.81M | $2.83 | 9+ qtrs | No change |
| 52 | Q32 Bio IncQTTB | — | 0.26% | $29.7M | 2.33M | $12.74 | 1 qtr | New |
| 53 | Anteris Technologies GlobalAVR | — | 0.26% | $29.6M | 3M | $9.85 | 2 qtrs | No change |
| 54 | Editas Medicine IncEDIT | — | 0.25% | $28.8M | 8.89M | $3.24 | 1 qtr | New |
| 55 | Ovid Therapeutics IncOVID | — | 0.25% | $28.2M | 10.5M | $2.69 | 3 qtrs | ▼ Reduced 2.0% |
| 56 | Assembly Biosciences IncASMB | — | 0.24% | $28M | 1.02M | $27.48 | 4 qtrs | No change |
| 57 | Alx Oncology Holdings IncALXO | — | 0.23% | $26.9M | 13.01M | $2.07 | 2 qtrs | No change |
| 58 | Benitec Biopharma IncBNTC | — | 0.22% | $24.8M | 1.85M | $13.38 | 3 qtrs | No change |
| 59 | Lenz Therapeutics IncLENZ | — | 0.21% | $23.7M | 4.18M | $5.68 | 9+ qtrs | No change |
| 60 | Lexeo Therapeutics IncLXEO | — | 0.20% | $23.3M | 5M | $4.66 | 3 qtrs | No change |
| 61 | Acrivon Therapeutics IncACRV | — | 0.19% | $21.8M | 12.23M | $1.78 | 9+ qtrs | ▲ Added 47% |
| 62 | Altimmune IncALT | — | 0.17% | $19.8M | 6.5M | $3.04 | 1 qtr | New |
| 63 | Karyopharm Therapeutics IncKPTI | — | 0.16% | $18.7M | 1.92M | $9.77 | 2 qtrs | No change |
| 64 | Bright Minds Biosciences IncDRUG | — | 0.16% | $18.6M | 265K | $70.20 | 2 qtrs | No change |
| 65 | Avalo Therapeutics IncAVTX | — | 0.16% | $18.5M | 1M | $18.48 | 8 qtrs | ▲ Added 51% |
| 66 | Onkure Therapeutics Inc-AOKUR | — | 0.16% | $18.2M | 4M | $4.56 | 2 qtrs | No change |
| 67 | Faeth Therapeutics IncFTH | — | 0.16% | $18.1M | 722.02K | $25.00 | 1 qtr | New |
| 68 | Aura Biosciences IncAURA | — | 0.15% | $17.8M | 2.5M | $7.10 | 1 qtr | New |
| 69 | Sab Biotherapeutics IncSABS | — | 0.15% | $17.2M | 4.4M | $3.90 | 4 qtrs | No change |
| 70 | Seaport Therapeutics IncSPTX | — | 0.13% | $15.2M | 700K | $21.72 | 1 qtr | New |
| 71 | Palisade Bio IncPALI | — | 0.13% | $14.9M | 7.12M | $2.09 | 3 qtrs | No change |
| 72 | Helix Acquisition CorpHLXC | — | 0.12% | $13.3M | 1.25M | $10.64 | 2 qtrs | No change |
| 73 | Waystar Holding CorpWAY | Technology | 0.09% | $10.9M | 529.4K | $20.53 | 3 qtrs | No change |
| 74 | Equillium IncEQ | — | 0.09% | $9.9M | 3.1M | $3.20 | 2 qtrs | No change |
| 75 | Macrogenics IncMGNX | — | 0.08% | $8.6M | 1.86M | $4.62 | 2 qtrs | No change |
| 76 | Perceptive Cap Solutionsno ticker on file | — | 0.07% | $8.2M | 750K | $10.88 | 9+ qtrs | No change |
| 77 | Adicet Bio IncACET | — | 0.07% | $8.1M | 932.62K | $8.64 | 9+ qtrs | ▼ Reduced 21% |
| 78 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.06% | $7.1M | 333.33K | $21.37 | 9+ qtrs | No change |
| 79 | Corvus Pharmaceuticals IncCRVS | — | 0.06% | $6.7M | 450K | $14.94 | 2 qtrs | No change |
| 80 | Rani Therapeutics Holdings-ARANI | — | 0.06% | $6.5M | 8.5M | $0.7604 | 3 qtrs | No change |
| 81 | Jatt II Acquisition CorpJATT | — | 0.05% | $5.7M | 500K | $11.36 | 1 qtr | New |
| 82 | Amanat Acquisition CorpAMAN | — | 0.03% | $3.8M | 375K | $10.16 | 1 qtr | New |
| 83 | Werewolf Therapeutics IncHOWL | — | 0.01% | $859.3K | 2.39M | $0.3599 | 9+ qtrs | ▼ Reduced 64% |
| 84 | Palatin Technologies IncPTN | — | 0.01% | $670.3K | 62.12K | $10.79 | 3 qtrs | ▼ Reduced 11% |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 42.6% | $4.9B | 8 |
| Technology | 0.09% | $10.9M | 1 |
| No sector on file | 57.3% | $6.6B | 75 |
Questions and answers
What did Peter Kolchinsky own in Q2 2026?
RA Capital Management's 13F for Q2 2026 lists 84 positions worth $11.5B. The largest: ASND (23.8%), PBLS (6.9%), RYTM (6.4%), PCVX (5.8%), SION (3.8%).
What did Peter Kolchinsky buy in Q2 2026?
The largest purchases, by the shares bought at the quarter-end price the filing implies: PBLS (new, $791.9M), COAG (new, $286.8M), ABVX (new, $150.9M), ORKA (new, $148M), ARTV (added, $78.6M), NTLA (new, $76.6M).
What did Peter Kolchinsky sell in Q2 2026?
The largest sales: DNTH (sold out, $219.2M), Nuvalent Inc (reduced, $159M), PRAX (sold out, $120.4M), SRPT (sold out, $84.9M), EWTX (reduced, $82.7M), SYRE (sold out, $81.8M).
When was this filing made?
RA Capital Management filed its 13F for the quarter ending Jun 30, 2026 on Aug 14, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio, Q2 2026: RA Capital Management 13F holdings”, data as of 14 August 2026. https://funkfolio.com/gurus/peter-kolchinsky/2026-q2
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Jun 30, 2026.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Jun 30, 2026, filed Aug 14, 2026. Changes compare share counts with the filing for Mar 31, 2026; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $11.5B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 9 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.